Hyperaldosteronism: Difference between revisions
No edit summary |
|||
Line 185: | Line 185: | ||
|Dexamethasone and/or mineralocorticoid blockers | |Dexamethasone and/or mineralocorticoid blockers | ||
|- | |- | ||
|Liddle’s syndrome | |Liddle’s syndrome (Pseudohyperaldosteronism type 1) | ||
|Mutation of the epithelial sodium channels (ENaC) gene in the distal renal tubules | |Mutation of the epithelial sodium channels (ENaC) gene in the distal renal tubules | ||
| | | | ||
Line 200: | Line 200: | ||
|The main pathogenetic mechanism is linked to the excess | |The main pathogenetic mechanism is linked to the excess | ||
of cortisol which saturates 11-HSD2 activity, allowing cortisol to bind MR. A similar picture is also related to over secretion of cortisol by adrenocortical carcinomas. In some cases the disease is associated with secondary hyperaldosteronism due to a direct activation of the renin angiotensin system by glucocorticoids. | of cortisol which saturates 11-HSD2 activity, allowing cortisol to bind MR. A similar picture is also related to over secretion of cortisol by adrenocortical carcinomas. In some cases the disease is associated with secondary hyperaldosteronism due to a direct activation of the renin angiotensin system by glucocorticoids. | ||
| | |Rapid [[Obesity|weight gain]], particularly of the [[trunk]] and [[face]] with [[limbs]] sparing ([[central obesity]]) | ||
| | * Proximal [[muscle weakness]] | ||
* A [[round face]] often referred to as a "[[moon face]]" | |||
* Excess [[sweating]] | |||
* [[Headache]] | |||
|Cortisol has mineralocorticoid effects | |||
|↓ | |↓ | ||
| | | | ||
Line 209: | Line 213: | ||
|Urinary free cortisol markedly ↑↑ | |Urinary free cortisol markedly ↑↑ | ||
| | | | ||
* [[Pasireotide]], [[Cabergoline]], [[Ketoconazole]], and [[Metyrapone]] | |||
* Adrenalectomy | |||
|- | |- | ||
|Insensitivity to glucocorticoids (Chrousos syndrome) | |Insensitivity to glucocorticoids (Chrousos syndrome) | ||
| | |Mutations in glucocorticoid receptor (GR) gene | ||
| | | | ||
* Hypertension | |||
* Adrenal hyperandrogenism | |||
|Deoxycorticosterone (DOC) | |Deoxycorticosterone (DOC) | ||
|↓ | |↓ | ||
|↓ | |↓ | ||
| | |Cortisol | ||
| | |Dexamethasone | ||
|- | |- | ||
|Aldosterone-secreting adrenocortical carcinoma | |Aldosterone-secreting adrenocortical carcinoma | ||
| | | | ||
| | | | ||
|Cortisol has mineralocorticoid effects | |||
|↓ | |||
| | | | ||
* ↓ if excess cortisol saturates 11-HSD2 enzyme activity | |||
| | * ↑ in direct activation of renin angiotensin system activation by glucocorticoids | ||
|Urinary free cortisol markedly ↑↑ | |||
| | | | ||
|- | |- | ||
Line 237: | Line 250: | ||
| | | | ||
|- | |- | ||
|Gordon’s syndrome | |Gordon’s syndrome (Pseudohypoaldosteronism type 2) | ||
| | |Mutations of at least four genes have been identified, including WNK1 and WNK4 | ||
| | | | ||
* Hypertension | |||
* Hyperkalemia | |||
* Normal renal function | |||
|No excess mineralocorticoid; an increased activity of the thiazide-sensitive Na–Cl co-transporter in the distal tubule | |||
|↓ | |↓ | ||
| | |Normal | ||
| | |Hyperkalemia | ||
|thiazide diuretics and/or dietary sodium restriction | |thiazide diuretics and/or dietary sodium restriction | ||
|- | |- |
Revision as of 20:34, 18 September 2017
Hyperaldosteronism Main page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
This page contains general information about Hyperaldosteronism. For more information on specific types, please visit the pages on Primary hyperaldosteronism, and Secondary hyperaldosteronism.
Synonyms and keywords: Aldosteronism
Overview
Classification
Aldosteronism and mineralocorticoid excess may be classified into two types, primary hyperaldosteronism (conn's syndrome) and secondary hyperaldosteronism. The different types of aldosteronism described in the below table:
Primary hyperaldosteronism | Category | Diseases | |||
---|---|---|---|---|---|
Adrenal causes |
|
||||
|
|||||
Extra-adrenal causes |
|
||||
Familial hyperaldosteronism |
|
||||
|
|||||
|
|||||
Other |
|
||||
|
|||||
Secondary hyperaldosteronism | Genetic mutation | Bartter and Gitelman syndromes | Hyperplasia of the juxtaglomerular apparatus (the source of renin in the kidney), | ||
Liddle syndrome or pseudohypoaldosteronism type 1 | due to resistance to the actions of aldosterone | ||||
Endocrine causes | Cushing syndrome | ||||
Ectopic ACTH production | |||||
Renovascular | Kidney transplant | ||||
Renin-secreting juxtaglomerular cell tumors | |||||
Scleroderma renal crisis | |||||
Malignant hypertension | |||||
Tumors | Reninoma | ||||
Intravascular hypovolemia | heart failure, hepatic cirrhosis, and nephrotic syndrome |
Pseudohyperaldosteronism causes:
Pseudohyperaldosteronism causes | Disease | Etiology | Clinical features | Labratory | ||||
---|---|---|---|---|---|---|---|---|
Elevated mineralocorticoid | Renin | Aldosterone | Other | Treatment | ||||
Endogenous causes | 17 alpha-hydroxylase deficiency | Mutations in the CYP17A1 gene |
|
Deoxycorticosterone (DOC) | ↓ | ↓ | Cortisol ↓ | Corticosteroids |
11β-hydroxylase deficiency | Mutations in the CYP11B1 gene |
|
Cortisol ↓ | |||||
Apparent mineralocorticoid excess syndrome (AME) | Genetic or acquired defect of 11-HSD
|
|
Cortisol has mineralocorticoid effects | ↓ | ↓ | Urinary free cortisone ↓↓ | Dexamethasone and/or mineralocorticoid blockers | |
Liddle’s syndrome (Pseudohyperaldosteronism type 1) | Mutation of the epithelial sodium channels (ENaC) gene in the distal renal tubules |
|
No extra mineralocorticoid presents, and mutations in Na channels mimic aldosterone mechanism | ↓ | ↓ | Cortisol ↓ | amiloride or triamterene can reverse the clinical picture reactivating the renin aldosterone | |
Cushing’s syndrome | The main pathogenetic mechanism is linked to the excess
of cortisol which saturates 11-HSD2 activity, allowing cortisol to bind MR. A similar picture is also related to over secretion of cortisol by adrenocortical carcinomas. In some cases the disease is associated with secondary hyperaldosteronism due to a direct activation of the renin angiotensin system by glucocorticoids. |
Rapid weight gain, particularly of the trunk and face with limbs sparing (central obesity)
|
Cortisol has mineralocorticoid effects | ↓ |
|
Urinary free cortisol markedly ↑↑ |
| |
Insensitivity to glucocorticoids (Chrousos syndrome) | Mutations in glucocorticoid receptor (GR) gene |
|
Deoxycorticosterone (DOC) | ↓ | ↓ | Cortisol | Dexamethasone | |
Aldosterone-secreting adrenocortical carcinoma | Cortisol has mineralocorticoid effects | ↓ |
|
Urinary free cortisol markedly ↑↑ | ||||
Geller’s syndrome | mutation of MR that alters its specificity and allows progesterone to bind MR | severe hypertension particularly during pregnancy | ↓ | ↓ | ||||
Gordon’s syndrome (Pseudohypoaldosteronism type 2) | Mutations of at least four genes have been identified, including WNK1 and WNK4 |
|
No excess mineralocorticoid; an increased activity of the thiazide-sensitive Na–Cl co-transporter in the distal tubule | ↓ | Normal | Hyperkalemia | thiazide diuretics and/or dietary sodium restriction | |
Exogenous causes | Corticosteroids with mineralocorticoid activity | |||||||
Hypersodic diets | ||||||||
Water intossications | ||||||||
Licorice ingestion | ↓ | ↓ | Urinary free cortisol Moderate ↑ | |||||
grapefruit | ||||||||
Contraceptives | ||||||||
Some progestins | ||||||||
Particular causes of hypertension | Sclerosis of juxtaglomerular apparatus (diabetic microangiopathy and/or of the elderly) | |||||||
FANS | ||||||||
B-Adrenergic agonists | ||||||||
Aging | ||||||||
Low-renin essential hypertension | ||||||||
Autonomic dysfunction | ||||||||
Partial/total nephrectomy or removal of renal tissue |
Differentiating Diagnosis
Hyperaldosteronism should be differentiated from other diseases causing hypertension and hypokalemia for example:
- Renal artery stenosis
- Cushing's syndrome
- Congenital adrenal hyperplasia (CAH)
- Liddle's syndrome
- Diuretic use
- Licorice ingestion
- Renin-secreting tumors
Hypertension and Hypokalemia | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plasma renin activity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Normal or High (Plasma Renin/Aldosterone ratio <10 | Suppressed (Plasma Renin/Aldosterone ratio >20 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
*Renin-secreting tumors *Diuretic use *Renovascular hypertension *Coarctation of aorta *Malignant phase hypertension | Urinary aldosterone | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Elevated | Normal | Low | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conn's syndrome (Primary aldosteronism) | Profound K+ depletion | • 17 alpha hydroxylase deficiency • 11 beta hydroxylase deficiency • Liddle's syndrome • Licorice ingestion • Deoxycortisone producing tumor | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Add Mineralocrticoid antagonist for 8 weeks | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BP response | No BP response | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
• Deoxycorticosterone excess( Tumor, 17 alpha hydroxylase and 11 beta hydroxylase deficiency) • Licorice ingestion •Glucocorticoid resistance | Liddle's syndrome) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||